Webinars

Immune checkpoint inhibitors promote anti-tumor immune responses by enhancing T-cell activity. Measuring the pharmacodynamic effects of these drug types presents a challenge as both the immune and cancer cell populations must be separated and assessed individually. Using a quantitative multiplex immunofluorescence assay (mIF) allows for in-depth cell phenotype characterization and spatial context. Researchers at Frederick National Laboratory for Cancer Research developed a robust mIF assay with InSituPlex® technology to better investigate T-cell activation states within the tumor microenvironment and across multiple patient tumor biopsies.

Next-generation multiplex fluorescence immunohistochemistry methods offer new capabilities for scientists to explore the biology of disease within patient tissues.This webinar will focus on user experiences using the Ultivue InSituPlex fluorescence multiplex IHC platform and provide insight and examples of how this technology can be applied in a research setting.